Facteau Bill 4

What Happened

• Bill Facteau, a director of BioCardia, was granted a derivative award of 8,000 shares (reported as an acquisition) on 2026-07-06. The Form 4 lists the price as $0.00 and a total reported value of $0.00.
• This award is a time‑based option-like grant: according to the filing footnote, 100% of the shares vest and become exercisable on the one‑year anniversary of the grant date, contingent on Facteau continuing as a service provider through that date. This is a compensation/award transaction rather than an open‑market purchase.

Key Details

• Transaction date: 2026-07-06; Form 4 filed: 2026-07-07 (appears timely).
• Transaction type/code: A (award/grant/acquisition); reported price per share: $0.00; reported total: $0.
• Vesting: 100% vests and becomes exercisable one year after grant, subject to continued service (Footnote F1).
• Shares owned after transaction: not specified in the filing.
• No 10b5-1 plan or withholding/tax sale noted; not an immediate sale or exercise.

Context

• This is a derivative award (option-like) that does not result in immediate ownership of free-trading shares until vesting/exercise conditions are met. Such director awards are common as compensation and do not by themselves indicate buying or selling sentiment. If/when the options vest and are exercised, there could be dilution—details like exercise price or post-exercise ownership would appear in future filings.